title: Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors.
abstract: Previous experiments reported desensitization to SS action in rat anterior pituitary cells and cell lines. The aim of the study was to verify whether the lack of desensitization to SS analogs (SSa) observed in acromegalic patients was also present in subjects with normal hypothalamic-pituitary function. The effect of chronic treatment with octreotide long-acting release (o-LAR, 10-30 mg/28 days) on IGF-I levels was then evaluated in 23 patients with gastroenteropancreatic (GEP) endocrine tumors (8 gastrinomas, 6 carcinoids, and 9 functioning pancreatic tumors). Serum IGF-I, clinical symptoms, plasma chromogranin-A (CgA) and markers of hepatic synthesis were evaluated before and after a short-term period in all the patients (median 4.5 months), after a medium-term period in 12 (median 18 months) and after a long-term follow-up period in 9 of them (median 48 months). Mean IGF-I levels decreased from 17.3+/-7.0 to 12.8+/-6.2 nmol/l in the short-term (p<0.005) being reduced from baseline concentrations in 87% and under the normal range for age in 35% of patients. Afterwards, they always remained stable both in the medium- and long-term periods, still being low in 3/12 and 2/9 patients, respectively. No alterations in biochemical markers of liver function were found either before or during therapy. No correlation between IGF-I levels, CgA concentrations and/or clinical definitive outcome was observed. In conclusion, the study demonstrated that: a) similarly to that observed in acromegalic patients, chronic o-LAR treatment did not induce desensitization of pituitary SS receptors (SSR) in humans with intact hypothalamic-pituitary axis, and b) in patients with GEP endocrine tumors, GH/IGF-I inhibition did not contribute to SSa efficacy.
authors.affiliation: Unit of Endocrinology, Department of Medical Sciences, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, 20122 Milan, Italy. cristina.ronchi@unimi.it
authors.forename: C L
authors.initials: CL
authors.lastname: Ronchi
authors.forename: M
authors.initials: M
authors.lastname: Peracchi
authors.forename: S
authors.initials: S
authors.lastname: Corbetta
authors.forename: S
authors.initials: S
authors.lastname: Massironi
authors.forename: C
authors.initials: C
authors.lastname: Ciafardini
authors.forename: D
authors.initials: D
authors.lastname: Conte
authors.forename: P
authors.initials: P
authors.lastname: Beck-Peccoz
authors.forename: A
authors.initials: A
authors.lastname: Spada
mesh_terms: D000328:Adult; D000368:Aged; D002276:Carcinoid Tumor / Q000097:blood / Q000188:drug therapy; D005260:Female; D015408:Gastrinoma / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007414:Intestinal Neoplasms / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000097:blood / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013995:Time
chemical_list: D013004:Somatostatin; D007334:Insulin-Like Growth Factor I